Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Long-Term Debt Repayments (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $465000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed 0.0% to $465000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 88.82% decrease, with the full-year FY2025 number at $1.9 million, down 88.19% from a year prior.
  • Long-Term Debt Repayments was $465000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $464000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $89.6 million in Q4 2021 to a low of -$73.6 million in Q1 2022.
  • A 5-year average of $2.5 million and a median of $268500.0 in 2023 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: plummeted 577.64% in 2022, then surged 67952.17% in 2024.
  • Aytu Biopharma's Long-Term Debt Repayments stood at $89.6 million in 2021, then crashed by 100.03% to -$26000.0 in 2022, then surged by 188.46% to $23000.0 in 2023, then surged by 1921.74% to $465000.0 in 2024, then changed by 0.0% to $465000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Long-Term Debt Repayments are $465000.0 (Q4 2025), $464000.0 (Q3 2025), and $464000.0 (Q2 2025).